| Literature DB >> 28258089 |
Xin Zhang1,2,3, Jing Li1, Juan-Juan Qin1,2,3, Wen-Lin Cheng1,2,3, Xueyong Zhu1,2,3, Fu-Han Gong1, Zhigang She1,2,3, Zan Huang4, Hao Xia5, Hongliang Li5,2,3.
Abstract
Oncostatin M (OSM) is a secreted cytokine mainly involved in chronic inflammatory and cardiovascular diseases through binding to OSM receptor β (OSMR-β). Recent studies demonstrated that the presence of OSM contributed to the destabilization of atherosclerotic plaque. To investigate whether OSMR-β deficiency affects atherosclerosis, male OSMR-β-/-ApoE-/- mice were generated and utilized. Here we observed that OSMR-β expression was remarkably upregulated in both human and mouse atherosclerotic lesions, which were mainly located in macrophages. We found that OSMR-β deficiency significantly ameliorated atherosclerotic burden in aorta and aortic root relative to ApoE-deficient littermates and enhanced the stability of atherosclerotic plaques by increasing collagen and smooth muscle cell content, while decreasing macrophage infiltration and lipid accumulation. Moreover, bone marrow transplantation of OSMR-β-/- hematopoietic cells to atherosclerosis-prone mice displayed a consistent phenotype. Additionally, we observed a relatively reduced level of JAK2 and signal transducer and activator of transcription (STAT)3 in vivo and under Ox-LDL stimulation in vitro. Our findings suggest that OSMR-β deficiency in macrophages improved high-fat diet-induced atherogenesis and plaque vulnerability. Mech-anistically, the protective effect of OSMR-β deficiency on atherosclerosis may be partially attributed to the inhibition of the JAK2/STAT3 activation in macrophages, whereas OSM stimulation can activate the signaling pathway.Entities:
Keywords: Janus kinase 2/signal transducer and activator of transcription 3; atherosclerosis; inflammation
Mesh:
Substances:
Year: 2017 PMID: 28258089 PMCID: PMC5408608 DOI: 10.1194/jlr.M074112
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922
The information for antibodies used in immunoblot
| Antibody | Product Code | Origin | Molecular Mass (kDa) |
| OSMR-β | Santa Cruz (sc30011) | Rabbit | 180 |
| p-JAK2 | CST (3776) | Rabbit | 125 |
| JAK2 | CST (3230) | Rabbit | 125 |
| p-STAT3 | CST (9145) | Rabbit | 86 |
| STAT3 | CST (4904) | Rabbit | 86 |
| p-STAT1 | CST (9167) | Rabbit | 91 |
| STAT1 | CST (9172) | Rabbit | 91 |
| p-STAT5 | Bioworld (BS4184) | Rabbit | 90 |
| STAT5 | Bioworld (BS1995) | Rabbit | 90 |
| CD36 | AbD (MCA2748) | Rat | 88 |
| ABCA-1 | Abcam (ab18180) | Mouse | 254 |
| GAPDH | CST (2118) | Rabbit | 37 |
Antibodies for Immunofluorescence staining
| Antibody | Concentration | Sources of Species | Catalog Number |
| Anti-Mac3 | 1:50 | Rat | 550292 |
| Anti-CD68 | 1:100 | Rat | MCA1957 |
| Anti-SMA | 1:100 | Mouse | ab7817 |
| Anti-p-STAT3 | 1:100 | Rabbit | 9145 |
| Anti-OSMR-β | 1:200 | Rabbit | Sc30011 |
Fig. 1.Enhanced OSMR-β expression in the atherosclerotic plaques of ApoE−/− mice and patients with CHD. A: The expression of OSMR-β in the coronary arteries of normal donors and patients with CHD (n = 4, *P < 0.05 versus donor). B: The expression of OSMR-β in aortas from ApoE−/− mice fed NC or a HFD (n = 4, *P < 0.05 versus control). C, D: Double immunofluorescence staining for OSMR-β (red) and Mac3 (macrophage, green) in the coronary arteries of normal donors and patients with CHD and in the aortic sinuses from ApoE−/− mice fed NC or a HFD (scale bar = 50 μm). The quantification was carried out by normalizing the fluorescence intensity of the OSMR-β-positive area with the Mac3-positive area in the atherosclerotic plaque. E: OSMR-β expression in BMDMs upon 15 μg/ml Ox-LDL stimulation for 24 h. *P < 0.05 versus control group.
Fig. 2.Deletion of OSMR-β ameliorated the development of atherosclerosis. A: Genotyping of OSMR-β−/−ApoE−/− mice and ApoE−/− littermates. B, C: En face analysis of aortas from OSMR-β−/−ApoE−/− mice and ApoE−/− littermates fed NC or a HFD; aortas were stained with Oil Red O (n = 10). D, E: Left panel, representative images of the aortic sinus or brachiocephalic arteries from OSMR-β−/−ApoE−/− and ApoE−/− mice stained with H&E. Right panel, quantification of the atherosclerotic lesion area (n = 6). *P < 0.05 compared with ApoE−/−.
Metabolic characteristics of OSMR-β−/−ApoE−/− mice and ApoE−/− mice
| Index | Timing | ApoE−/− | OSMR-β−/−ApoE−/− | |
| Body weight (g) | Before HFD | 23.89 ± 0.37 | 25.57 ± 0.83 | 0.075 |
| 28 week HFD | 35.03 ± 1.26 | 34.60 ± 1.39 | 0.819 | |
| TG (mg/dl) | 28 week HFD | 81.17 ± 0.48 | 83.56 ± 0.80 | 0.684 |
| TC (mg/dl) | 28 week HFD | 513.88 ± 6.20 | 510.49 ± 6.72 | 0.715 |
| VLDL (mg/dl) | 28 week HFD | 542.66 ± 5.86 | 553.12 ± 6.50 | 0.247 |
| LDL (mg/dl) | 28 week HFD | 346.32 ± 3.32 | 355.39 ± 3.69 | 0.085 |
| IDL (mg/dl) | 28 week HFD | 210.5 ± 2.89 | 216.38 ± 6.38 | 0.417 |
| HDL (mg/dl) | 28 week HFD | 50.16 ± 0.98 | 48.33 ± 0.23 | 0.099 |
TG, triglyceride; TC, total cholesterol.
Fig. 3.OSMR-β ablation reduces the area of necrotic core and enhances plaque stability. A, B: Left panel, representative images used to analyze the necrotic area in aortic roots and brachiocephalic arteries from OSMR-β−/−ApoE−/− and ApoE−/− mice. Right panel, quantitation of the necrotic area (n = 6). C–E: Histological analysis of plaque stability in the aortic sinus. C: PSR staining for the detection of collagen content. D: Immunofluorescence analysis of SMA for the detection of SMC content. E: Immunofluorescence analysis of CD68 for the detection of macrophage infiltration. F: Oil Red O staining for the detection of lipid accumulation. *P < 0.05 versus ApoE−/−.
Fig. 4.OSMR-β deficiency decreases atherosclerosis-induced inflammation. A: Real-time PCR analysis of pro-inflammatory cytokine expression in the whole aortas of OSMR-β−/−ApoE−/− and ApoE−/− mice compared with CD68 expression (n = 3). B: Detection of MCP-1, TNF-α, IL-6, and IL-1β expression in the serum with ELISA (n = 6). *P < 0.05 compared with ApoE−/−.
Fig. 5.OSMR-β deficiency inhibits the activation of JAK2/STAT3 signaling. A: Western blot analysis of the expression of phosphorylated and total JAK2, STAT3, STAT1, and STAT5 in the whole aortas of OSMR-β−/−ApoE−/− and ApoE−/− littermates. Quantitation of relative phosphorylated protein expression after normalization to each total protein expression, respectively (n = 3). B: Immunofluorescence costaining of phosphorylated STAT3 (green) and CD68 (red) in atherosclerotic plaques (scale bar = 50 μm). C: Western blot analysis of phosphorylated and total JAK2 and STAT3 in peritoneal macrophages from OSMR-β−/−ApoE−/− and ApoE−/− littermates upon 15 μg/ml Ox-LDL treatment for 24 h. The results present phosphorylated protein expression compared with the total protein expression, respectively (n = 3). D: The JAK2 and STAT3 expression in macrophages from ApoE−/− mice upon PBS or OSM treatment. *P < 0.05 compared with control group.
Fig. 6.The absence of OSMR-β from bone marrow-derived cells attenuates atherogenesis. A: DNA was isolated from whole blood for genotyping to confirm genome reorganization with PCR. B: Left panel, Oil Red O staining for en face analysis of atherosclerotic plaques in aortas from OSMR-β−/−ApoE−/−→ApoE−/− (n = 8) and ApoE−/−→ApoE−/− (n = 10) mice. Right panel, analysis of the atherosclerotic lesion area (n = 10 or 8, each group). C: Left panel, H&E staining of the aortic root from OSMR-β−/−ApoE−/−→ApoE−/− mice and ApoE−/−→ApoE−/− mice. Right panel, quantification of the atherosclerotic lesion area (scale bar = 500 μm, n = 6). D: Oil Red O staining of peritoneal macrophages from OSMR-β−/−ApoE−/−→ApoE−/− mice and ApoE−/−→ApoE−/− mice treated with Ox-LDL. E: Western blot analysis of CD36 and ABCA-1 expression in OSMR-β−/−ApoE−/−→ApoE−/− and ApoE−/−→ApoE−/− mice. F: Real-time PCR analysis of pro-inflammatory cytokine expression in macrophages from OSMR-β−/−ApoE−/−→ApoE−/− mice and ApoE−/−→ApoE−/− mice treated with Ox-LDL (n = 3). *P < 0.05 compared with ApoE−/−→ApoE−/− group.